5 studies found for:    tedizolid | Phase 3 | Industry
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Condition: Bacterial Infections
Interventions: Drug: Tedizolid (BAY119-2631);   Drug: Placebo Tedizolid (BAY119-2631);   Drug: Linezolid;   Drug: Placebo Linezolid
Phase: Phase 3
2 Completed TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.
Condition: Skin and Subcutaneous Tissue Bacterial Infections
Interventions: Drug: TR-701 FA;   Drug: Linezolid
Phase: Phase 3
3 Recruiting A Phase III Study to Evaluate the Efficacy and Safety of BAY 1192631 in Japanese Patients With MRSA Infections (SSTI and SSTI-related Bacteremia).
Condition: Skin Diseases, Infectious
Interventions: Drug: Tedizolid(BAY1192631);   Drug: Linezolid
Phase: Phase 3
4 Completed TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Condition: Skin and Subcutaneous Tissue Bacterial Infections
Interventions: Drug: TR-701 FA for 6 days followed by 4 days of placebo;   Drug: Linezolid for 10 days of treatment
Phase: Phase 3
5 Recruiting TR-701 FA vs Linezolid for the Treatment of Nosocomial Pneumonia
Condition: Pneumonia
Interventions: Drug: TR-701 FA IV;   Drug: Linezolid
Phase: Phase 3

Indicates status has not been verified in more than two years